Celgene Corp (CELG) 120.02 $CELG Midday Glance:

New Post Public Reply Private Reply Replies (0) Message Board

Mar 30, 2015 at 5:34 PM

Celgene Corp (CELG) 120.02 $CELG

Midday Glance: Biotechnology companies
AP - Mon Mar 30, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)

Early Glance: Biotechnology companies
AP - Mon Mar 30, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)

Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), HD: 114.63 (+0.77), RYL: 48.91 (+0.73), ALTR: 42.82 (-1.57), AMGN: 164.30 (+1.71), XOM: 85.63 (+2.05), INTC: 31.46 (-0.54), CELG: 120.02 (+1.34), LEN: 51.49 (+1.06), CVX: 106.90 (+2.62), TOL: 39.21 (-0.01), REGN: 459.78 (+5.28)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 137.51 (+2.47), BIIB: 431.62 (+1.75), F: 16.16 (+0.18), LMT: 204.89 (+2.66), SHAK: 49.62 (+0.62), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), RTN: 110.99 (+1.06), NOC: 162.68 (+2.20), GMCR: 113.96 (+0.76), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), JACK: 97.04 (+0.73), KMX: 69.22 (+2.53), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), REGN: 459.78 (+5.28), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), NXPI: 102.43 (+2.51), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), CELG: 120.02 (+1.34), MS: 36.31 (+0.48), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), GILD: 100.69 (-0.31), NDLS: 17.54 (-0.06), GM: 37.68 (+0.37), MCD: 97.88 (+0.92), DOW: 48.68 (+0.92), AVGO: 130.55 (+2.34), LLL: 126.69 (+1.46)

Final Glance: Biotechnology companies
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)

A Buyback Or Biotech Bubble?
Leo Kolivakis - Seeking Alpha - Fri Mar 27, 1:37PM CDT
(click to enlarge) Steven Davidoff Solomon, professor of law at the University of California, Berkeley, wrote a comment for the New York Times reports, General Motors' Stock Buyback Follows a Worrying Trend : General Motors' announcement that...
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), PKW: 49.69 (+0.67), CELG: 120.02 (+1.34)

Jim Cramer -- There's No Bubble in Biotech or Semiconductor Sectors
at The Street - Fri Mar 27, 10:23AM CDT
Some of Cramer's favorite companies are rising with their sectors Friday.
BIIB: 431.62 (+1.75), QRVO: 81.40 (+2.12), SWKS: 100.13 (+1.30), IBB: 351.32 (+3.86), SMH: 55.86 (+0.47), NXPI: 102.43 (+2.51), REGN: 459.78 (+5.28), AVGO: 130.55 (+2.34), CELG: 120.02 (+1.34)

Wait For The Big Biotechs To Stabilize - Cramer's Lightning Round (3/26/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 27, 5:00AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 26. Bullish Calls: Halliburton (NYSE: HAL ): "Please do not sell it. We are finally getting to levels where I think that the worst is priced...
DVAX: 23.14 (+0.44), GPRO: 43.58 (+0.88), SWKS: 100.13 (+1.30), GRUB: 46.23 (+0.89), HAL: 43.82 (+0.56), HIMX: 6.43 (-0.17), MAR: 81.50 (+0.68), H: 59.01 (+0.31), CSCO: 27.65 (+0.52), KERX: 13.04 (+0.34), CELG: 120.02 (+1.34)

Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 5:50PM CDT
Agios Pharmaceuticals (AGIO) announced that its PK deficiency candidate, AG-348 has been granted orphan drug status by the FDA.
LCI: 67.86 (+2.35), CBM: 35.59 (+0.66), AGIO: 98.80 (+2.20), CELG: 120.02 (+1.34)

Stocks Turn Flat in Bumpy Session; Crude Settles Above $51
at The Street - Thu Mar 26, 1:53PM CDT
Stocks recover from heavy losses suffered earlier Thursday.
IBB: 351.32 (+3.86), MYL: 60.00 (-1.63), LULU: 64.83 (+0.51), SLB: 84.48 (+1.17), CELG: 120.02 (+1.34), GILD: 100.69 (-0.31), ALXN: 180.26 (-0.33), RHT: 76.69 (+0.17), TWC: 149.27 (+1.99), CMCSA: 56.61 (+0.67)

Celgene backs away from development of mAb for blood cancer
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 12:04PM CDT

CELG: 120.02 (+1.34)

Biotech Stock Selloff: Is It Justified?
at Investor's Business Daily - Thu Mar 26, 11:12AM CDT
Biotech stocks continued to slide Thursday, prompting analysts to weigh in on the causes and prognosis for the sector. Piper Jaffray's Joshua Schimmer noted that the same thing happened about a year ago, sparked by the price debate over Gilead...
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), KITE: 59.98 (+0.20), GILD: 100.69 (-0.31), ALXN: 180.26 (-0.33), JUNO: 60.66 (+4.06), CELG: 120.02 (+1.34)

Today's Market: Biotech Correction, Social Media News And Geopolitical Events Moving Stocks
Matthew Smith - at Seeking Alpha - Thu Mar 26, 9:10AM CDT

YHOO: 44.95 (-0.15), BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), FB: 83.19 (-0.11), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), AMGN: 164.30 (+1.71), GOOGL: 561.13 (+3.58), TWTR: 49.89 (-0.12), GOOG: 552.03 (+3.69), CELG: 120.02 (+1.34)

'Fast Money' Recap: The 3 Reasons Stocks Tanked Wednesday
at The Street - Thu Mar 26, 4:00AM CDT
The trading panel discussed the declines in biotech, transports and semiconductors.
FDX: 166.75 (+2.16), BIIB: 431.62 (+1.75), MU: 26.68 (+0.01), OIH: 33.90 (+0.32), XBI: 224.37 (+4.96), AMGN: 164.30 (+1.71), BNO: 20.93 (+0.06), IBB: 351.32 (+3.86), SMH: 55.86 (+0.47), INTC: 31.46 (-0.54), TLT: 130.41 (-0.65), CELG: 120.02 (+1.34), NVDA: 21.47 (+0.09), SAN: 7.50 (+0.03), SAVE: 78.30 (+1.66), GILD: 100.69 (-0.31), QCOM: 68.88 (+1.85), IYT: 157.46 (+1.46)

Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
71.14 (+0.75), UTX: 118.83 (+1.93), KRFT: 90.61 (+1.51), PAH: 26.15 (+0.49), INTC: 31.46 (-0.54), PVH: 105.36 (+1.45), VG: 4.93 (-0.05), DFS: 56.79 (+0.22), RYAAY: 66.00 (-0.20), PAYX: 50.01 (+0.46), SONC: 32.29 (+0.23), MWV: 50.52 (+1.03), COST: 152.36 (+1.89), ABBV: 58.24 (+0.59), MMP: 79.04 (+0.41), REGN: 459.78 (+5.28), CSCO: 27.65 (+0.52), URI: 91.86 (+1.81), ROVI: 18.84 (+0.36), AVP: 7.90 (+0.03), KR: 77.24 (+0.91), FB: 83.19 (-0.11), IP: 55.21 (+0.79), PFE: 35.00 (+0.47), DIS: 106.12 (+0.64), COP: 64.00 (+1.07), AMGN: 164.30 (+1.71), WFC: 54.77 (+0.65), DENN: 11.49 (-0.06), CELG: 120.02 (+1.34), WWAV: 44.64 (-0.59), ISIS: 64.81 (+1.44), FPRX: 23.76 (+1.23)

Look for Shares of Celgene to Potentially Rebound after Yesterday's 4.22% Sell Off
Comtex SmarTrend(R) - Wed Mar 25, 3:58PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $116.77 to a high of $123.37. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $121.78 on volume of 8.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 120.02 (+1.34)

After Yesterday's Decline of 4.22%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 25, 3:58PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $116.77 to a high of $123.37. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $121.78 on volume of 8.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 120.02 (+1.34)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...